Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pulmonary Emphysema in Alpha-1 PI Deficiency”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Large-scale testing (Phase 3)Enrolling By InvitationNCT02796937
What this trial is testing

Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency

Who this might be right for
Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency
Grifols Therapeutics LLC 290
Large-scale testing (Phase 3)Active Not RecruitingNCT01983241
What this trial is testing

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Who this might be right for
Pulmonary Emphysema in Alpha-1 PI Deficiency
Grifols Therapeutics LLC 345
Testing effectiveness (Phase 2)Study completedNCT04722887
What this trial is testing

Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Who this might be right for
Alpha1-Antitrypsin Deficiency
Grifols Therapeutics LLC 17
Large-scale testing (Phase 3)Looking for participantsNCT07555483
What this trial is testing

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

Who this might be right for
Alpha 1 Antitrypsin Deficiency
Grifols Therapeutics LLC 40
Post-approval studies (Phase 4)Study completedNCT00396006
What this trial is testing

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Who this might be right for
Alpha 1-Antitrypsin Deficiency
Baxalta now part of Shire 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT06405633
What this trial is testing

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

Who this might be right for
Alpha-1 Antitrypsin Deficiency
Wave Life Sciences USA, Inc. 24
Testing effectiveness (Phase 2)Study completedNCT01213043
What this trial is testing

Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency

Who this might be right for
EmphysemaAlpha 1-antitrypsin Deficiency (AATD)
Grifols Therapeutics LLC 30
Testing effectiveness (Phase 2)Study completedNCT03679598
What this trial is testing

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Who this might be right for
Alpha-1 Antitrypsin Deficiency (AATD)Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I MutationsEmphysema or COPD
University of Alabama at Birmingham 63